Sabra Healthcare REIT: The Occupancy Recovery That Guidance Depends On

Sabra Health Care REIT reports second-quarter earnings on August 3, 2026, with analysts expecting $0.38 per share — flat year-over-year but representing the company's fourth consecutive quarter of beating estimates. The central question is whether management's raised full-year guidance and portfolio repositioning efforts can sustain momentum in a healthcare real estate sector facing operational headwinds and elevated interest rates.

Part 1: Earnings Preview

Sabra Health Care REIT (SBRA) is a healthcare-focused real estate investment trust that owns and invests in skilled nursing, senior housing, and behavioral health facilities across the United States. The company generates revenue primarily through triple-net lease arrangements and senior housing management agreements with healthcare operators.

Sabra reports Q2 2026 earnings after market close on August 3, 2026, with the consensus estimate at $0.38 per share from 2 analysts. The company most recently reported $0.39 per share for Q1 2026, beating the $0.38 estimate by 2.63%. The Q2 estimate of $0.38 matches the $0.38 reported in the year-ago quarter, suggesting flat year-over-year growth as the company navigates its portfolio transformation.

For full-year 2026, analysts expect $1.51 per share, representing 1.34% growth over 2025, with 2027 estimates calling for acceleration to $1.59 (+5.30% growth). Revenue estimates for Q2 stand at $216.71 million according to available analyst projections.

Three key themes define this earnings story:

Portfolio Repositioning and Concentration Risk: Management has been actively reducing exposure to higher-risk segments, with behavioral health concentration declining from 13% to 9% of annualized cash NOI. The company recently issued updated guidance incorporating transaction activity and operational performance, signaling confidence in the strategic pivot toward more stable asset classes. Investors will scrutinize whether this repositioning is translating into improved portfolio quality metrics.

Balance Sheet Deleveraging: Sabra's Net Debt to EBITDA improved from 5.0x to 4.8x as of mid-2026, demonstrating progress on financial flexibility. With interest rates remaining elevated, the company's ability to continue reducing leverage while funding growth investments will be critical to maintaining its dividend capacity and accessing capital markets on favorable terms.

Senior Housing Recovery Trajectory: Management's guidance assumes low-to-mid teens Cash NOI growth for the same-store Senior Housing - Managed portfolio, reflecting ongoing occupancy and rate improvements in this segment. The sustainability of this recovery — particularly labor cost trends and demand patterns — will be a focal point for investors assessing the durability of earnings growth beyond 2026.

Analyst commentary ahead of the release reflects cautious optimism, with 6 Strong Buy ratings among the 17 analysts covering the stock. The consensus price target of $22.71 implies modest upside from current levels, suggesting the market is waiting for confirmation that operational improvements can offset the headwinds facing healthcare REITs broadly.

Part 2: Historical Earnings Performance

Sabra has established a consistent pattern of beating earnings estimates, delivering positive surprises in each of the past four quarters. The company reported $0.38 in Q2 2025 (beating the $0.36 estimate by 5.56%), $0.38 in Q3 2025 (beating $0.37 by 2.70%), $0.38 in Q4 2025 (beating $0.37 by 2.70%), and most recently $0.39 in Q1 2026 (beating $0.38 by 2.63%).

The magnitude of beats has been relatively modest but remarkably stable, ranging from 2.63% to 5.56%, with the average surprise around 3.4%. This consistency suggests management has been effectively managing expectations while executing on operational initiatives. The sequential EPS progression from $0.38 to $0.39 in the most recent quarter, while small, represents the first quarterly increase in this four-quarter window.

The trend reflects improving operational execution as the company works through its portfolio transformation. With estimates holding steady at $0.38 for the upcoming Q2 2026 report — matching the year-ago result — analysts appear to be taking a conservative stance, potentially setting up for another modest beat if recent patterns hold.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Sabra typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior shows moderate volatility around Sabra's earnings releases, with the stock averaging an absolute move of 1.17% on Day 0 and 2.04% on Day +1. Intraday ranges are wider, averaging 2.18% on Day 0 and 4.71% on Day +1, indicating significant intraday volatility even when closing moves are contained.

The direction of moves has been mixed, with no clear pattern of consistent post-earnings rallies or selloffs. The most recent report on April 29, 2026 saw a modest decline of 0.78% on Day 0 followed by a 1.52% gain on Day +1. The largest recent move came after the November 2025 report, which produced a 3.57% Day +1 gain, while the October 2024 report triggered a sharp 3.92% Day +1 decline.

Investors should anticipate a 2-5% trading range in the session following results, with the ultimate direction likely determined by guidance commentary and portfolio metrics rather than the headline EPS figure alone, given the company's track record of modest but consistent beats.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 0.80% for the August 21 expiration, significantly below the stock's average historical Day +1 move of 2.04% and well under the average Day +1 range of 4.71%. This suggests options traders are anticipating a relatively muted reaction compared to recent earnings events, potentially reflecting confidence in management's raised guidance and the company's consistent execution.

Part 3: What Analysts Are Saying

Analyst sentiment on Sabra reflects cautious optimism, with the consensus rating at 3.59 (between Hold and Buy) and an average price target of $22.71 — implying approximately 7.3% upside from the current price of $21.17. The analyst community is divided, with 6 Strong Buys, 10 Holds, and 1 Strong Sell among the 17 analysts covering the stock.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 5 to 6, while the average recommendation ticked up from 3.50 to 3.59. This modest upgrade suggests growing confidence in the company's strategic repositioning and improved balance sheet metrics, though the large Hold contingent indicates many analysts are waiting for further proof of execution before turning more bullish.

The price target range is relatively tight, spanning from a low of $19.00 to a high of $25.00, with the mean target of $22.71 sitting near the middle of that band. The 18% spread between the high and low targets reflects reasonable consensus on valuation, with bulls seeing potential for the stock to reach $25 if the senior housing recovery accelerates and leverage continues declining, while bears see downside to $19 if operational challenges resurface or interest rates remain elevated longer than expected.

Part 4: Technical Picture

Sabra's technical setup heading into earnings shows improving momentum, with the Barchart Technical Opinion currently at 72% Buy, unchanged from last week but representing a dramatic improvement from the 8% Sell signal registered just one month ago. This sharp reversal reflects the stock's recent strength as it has climbed above key moving averages.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the earnings release
• Medium-term (Hold): Neutral reading suggests the intermediate trend is in transition as the stock works to establish a new range
• Long-term (100% Buy): Strong buy signal reflects a positive longer-term trend structure supporting the recent advance

Trend Characteristics: The trend is characterized as Good strength but Weakening direction, suggesting momentum remains positive but may be losing steam after the recent rally — a setup that makes the earnings reaction particularly important for determining whether the uptrend can extend or needs to consolidate.

The stock is trading at $21.17, positioned above its 20-day ($20.81), 50-day ($19.84), 100-day ($20.08), and 200-day ($19.56) moving averages, but below its shorter-term 5-day ($21.84) and 10-day ($21.76) averages. This configuration suggests a healthy intermediate-term uptrend with recent short-term consolidation near the $21 level. The 50-day average at $19.84 represents key support, while the recent highs near $21.84 mark immediate resistance. The overall technical setup is moderately supportive heading into earnings, with the stock having established a cushion above longer-term averages but facing a test of whether it can break through recent resistance on positive results. A beat-and-raise scenario could propel the stock toward the $22.71 analyst price target, while any disappointment risks a pullback toward the 50-day support zone.